Evidence map›Paper›PMID 33893301›Full record

ArticleNature communications2021

RANKL regulates male reproductive function.

Martin Blomberg Jensen, Christine Hjorth Andreassen, Anne Jørgensen, John Erik Nielsen, Li Juel Mortensen, Ida Marie Boisen, Peter Schwarz, Jorma Toppari, Roland Baron, Beate Lanske and 1 more

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05212337 phase2active not recruitingnot on this mapstarted 2022, after this paper: background citation

Effect of a Single-dose Denosumab on Semen Quality in Infertile Men (FITMI): A Randomized Controlled Trial

TypeinterventionalSponsorMartin Blomberg JensenRan2022 to 2025Enrolled180ConditionsInfertility, MaleArmsDenosumab, Sodium chloride
NCT06300229 phase1 / phase2completednot on this mapstarted 2024, after this paper: background citation

Novel Approach for Oligospermia (NAPO): A Randomized Controlled Trial

TypeinterventionalSponsorMartin Blomberg JensenRan2024 to 2025Enrolled42ConditionsInfertility, MaleArmsDenosumab, sodium chloride
NCT06706414 phase1 / phase2active not recruitingnot on this mapstarted 2025, after this paper: background citation

Novel Treatment of Some Men With Non-Obstructive Azoospermia (NT-NOA): A Clinical Interventional Study

TypeinterventionalSponsorMartin Blomberg JensenRan2025 to 2026Enrolled16ConditionsInfertility, MaleArmsDenosumab (Prolia), Letrozole (Aromatase Inhibitors)
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 58 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Recent Progress of In Vitro 3D Culture of Male Germ Stem Cells.Journal of functional biomaterials · 2023
    Review
  16. Loss of Adgra3 causes obstructive azoospermia with high penetrance in male mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Martin Blomberg JensenGroup of Skeletal, Mineral and Gonadal Endocrinology, Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. blombergjensen@gmail.com.ORCID 0000-0003-3800-4253
Christine Hjorth Andreassen *Group of Skeletal, Mineral and Gonadal Endocrinology, Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-3643-6426
Anne Jørgensen *Department of Growth and Reproduction and International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-6409-198X
John Erik NielsenDepartment of Growth and Reproduction and International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Li Juel MortensenGroup of Skeletal, Mineral and Gonadal Endocrinology, Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Ida Marie BoisenGroup of Skeletal, Mineral and Gonadal Endocrinology, Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Peter SchwarzDepartment of Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-0483-8594
Jorma ToppariInstitute of Biomedicine, Research Centre for Integrated Physiology and Pharmacology, and Centre for Population Health Research, University of Turku, and Department of Pediatrics, Turku University Hospital, Turku, Finland.
Roland BaronDivision of Bone and Mineral Research, HSDM/HMS, Harvard University, Boston, MA, USA.ORCID 0000-0001-5784-5934
Beate LanskeDivision of Bone and Mineral Research, HSDM/HMS, Harvard University, Boston, MA, USA.
Anders JuulDepartment of Growth and Reproduction and International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
University of Copenhagen · DKHarvard University · USUniversity of Turku · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infertile men have few treatment options. Here, we demonstrate that the transmembrane receptor activator of NF-kB ligand (RANKL) signaling system is active in mouse and human testis. RANKL is highly expressed in Sertoli cells and signals through RANK, expressed in most germ cells, whereas the RANKL-inhibitor osteoprotegerin (OPG) is expressed in germ and peritubular cells. OPG treatment increases wild-type mouse sperm counts, and mice with global or Sertoli-specific genetic suppression of Rankl have increased male fertility and sperm counts. Moreover, RANKL levels in seminal fluid are high and distinguishes normal from infertile men with higher specificity than total sperm count. In infertile men, one dose of Denosumab decreases RANKL seminal fluid concentration and increases serum Inhibin-B and anti-Müllerian-hormone levels, but semen quality only in a subgroup. This translational study suggests that RANKL is a regulator of male reproductive function, however, predictive biomarkers for treatment-outcome requires further investigation in placebo-controlled studies.

Indexed as

AnimalsAnti-Mullerian HormoneDenosumabFertilityHumansInhibinsMaleMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicOsteoprotegerinRANK LigandSemenSemen AnalysisSertoli CellsAnti-Mullerian HormoneDenosumabinhibin BInhibinsOsteoprotegerinRANK Ligand

Identifiers

PMID33893301
PMCPMC8065035
OpenAlexW3153767170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.